Dupixent MDL discovery stay: why CTCL records still matter before the October conference

✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Last reviewed: September 24, 2026.

The Dupixent CTCL MDL is not moving in a dramatic way right now. That is
the point. The court is doing the early housekeeping: pausing formal
discovery, holding off on answer deadlines, and getting everyone ready
for the first management conference.

For a family trying to make sense of a CTCL diagnosis, that can feel
like nothing is happening. But the medical paper trail is still moving
in the background, and it is usually harder to rebuild later.

If you or someone in your family used Dupixent and was later diagnosed
with cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, or
another T-cell lymphoma being reviewed by counsel, the useful work right
now is not guessing when a settlement may happen. There is no announced
settlement. The practical work is simpler: save the records that show
the diagnosis, the timing, and the way doctors confirmed it.

Our main [Dupixent lawsuit hub](https://masstortamerica.com/mass-
torts/dupixent/) explains the broader allegations against Sanofi and
Regeneron. This article is narrower. It looks at the court's early
discovery stay and why patients should still gather CTCL records before
the October 1, 2026 initial management conference.

What the discovery stay actually means

Judge Quraishi's Initial Procedure Order No. 1 set the first in-person
management conference for October 1, 2026 in Trenton, New Jersey. It
also required the parties to submit a joint initial management report by
September 10.

The same order stayed defendants' answer deadlines and stayed formal
discovery while the court sets the MDL structure. Put plainly, the
lawyers are not yet in the full evidence-exchange phase. That is common
at the front end of a products MDL.

The stay should not be read as a ruling for either side. It does not
decide whether Dupixent caused or accelerated anyone's lymphoma. It does
not say the warnings were adequate or inadequate. And it does not create
a settlement program.

The JPML transfer order described the shared questions the MDL will
eventually have to work through: whether the scientific literature
supports a causal link between Dupixent and CTCL, when the companies
should have learned about any such link, and whether the warnings were
adequate.

Why records still matter before discovery opens

A court stay on formal discovery is not the same thing as a pause on
your medical history. Dermatology and oncology records can be scattered
across different offices, portals, pathology labs, pharmacies, and
hospitals. Some are easy to download. Others require signed requests and
follow-up calls.

For a Dupixent CTCL review, the records that usually matter most are
specific:

Dupixent prescription and injection history, including start date, dose changes, and stop date.
Dermatology notes from before and during Dupixent treatment, especially notes describing eczema, rash, plaques, nodules, or treatment-resistant skin changes.
Biopsy, pathology, and immunohistochemistry reports used to confirm CTCL, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma.
Oncology records, staging notes, imaging, lab reports, and treatment plans.
Photos or patient-portal messages that show how the skin condition changed over time, if they exist and can be preserved without editing.

Those records do two things. First, they help counsel decide whether the
case fits the current CTCL-centered MDL. Second, they protect the
timeline. Memories fade quickly when a skin problem stretches across
months or years and several doctors.

The MDL is focused, but the boundary issue is still important

The JPML order says most plaintiffs used Dupixent, commonly for atopic
dermatitis, and were later diagnosed with CTCL. It also says some claims
were brought by spouses or survivors.

The panel did not finally decide whether every non-cutaneous T-cell
lymphoma belongs in the MDL. It left that issue for possible
conditional-transfer proceedings later. That distinction matters for
families who have heard broad online language about "lymphoma" but whose
records use a more precise diagnosis.

Do not smooth over the diagnosis. The pathology wording matters. CTCL,
mycosis fungoides, Sézary syndrome, peripheral T-cell lymphoma, and
anaplastic large cell lymphoma are not interchangeable labels. A lawyer
reviewing a claim needs the exact diagnosis used by the treating doctors
and pathology lab.

What claimants should not assume from the October conference

The October 1 conference is a setup conference. It may lead to orders
about leadership, discovery sequencing, direct filing, census forms,
protective orders, future conferences, or master pleadings. It is not
expected to be a trial. It is not a compensation hearing.

That is why we would be cautious about any claim that a Dupixent
settlement is already scheduled or that a specific payout number is
available. Public sources do not show that. The better reading is
simpler: the MDL is moving from transfer into case management, and the
court is deciding how the early work will be organized.

If a later census or plaintiff fact sheet is ordered, patients who
already have pharmacy records, dermatology notes, and pathology reports
will be in a better position to answer basic questions accurately.

Questions families can ask while gathering records

These questions are not a medical diagnosis tool. They are a way to make
the record review cleaner:

When did Dupixent start, and why was it prescribed?
What skin symptoms existed before treatment, and what changed during or after treatment?
Was CTCL first suspected by a dermatologist, oncologist, pathologist, or another doctor?
Which biopsy or pathology report confirmed the diagnosis?
Were there earlier biopsies that were negative, inconclusive, or read as eczema or dermatitis?
Did any doctor mention mycosis fungoides, Sézary syndrome, or another T-cell lymphoma subtype?

When possible, tie each answer to a document. A portal note or pathology
report usually carries more weight than memory alone.

Related Mass Tort America resources

Dupixent lawsuit hub
Current mass tort lawsuits
Ozempic and GLP-1 lawsuit hub, for another example of how MDL medical records and diagnostic proof can shape drug-injury screening

A few cautions before you rely on the docket

The MDL is not a class action. Each person's claim still depends on that
person's use of Dupixent, diagnosis, timing, records, and filing
deadline. The discovery stay also should not be treated as a pause on
any statute of limitations. Public orders show case-management steps,
not a ruling that Dupixent caused CTCL and not a settlement.

Attorney advertising and informational disclaimer

This article is for general information and may be attorney advertising.
It is not medical advice and does not create an attorney-client
relationship. You should speak with a doctor about medical questions and
with a lawyer about deadlines that may apply to your claim.

Sources

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →